Intrinsiqs

Is The Joint Corp. overvalued?

The Joint Corp. (JYNT) looks overvalued — trading about 35% above its fair value.

Overvalued
Current price $6.94 Fair value $4.50
Price
$6.94
Fair value
$4.50
Current P/E
69.4
Normal P/E
45.0
Market cap
$95.0M
Dividend yield
0.0%
Return on equity
19.3%
Sector
Healthcare

See the full interactive analysis →

Fair value compares JYNT's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.

Related stocks

LLY Eli Lilly and CompanyJNJ Johnson & JohnsonABBV AbbVie Inc.RHHBY Roche Holding AGUNH UnitedHealth Group IncorporatedMRK Merck & Co., Inc.